Karina Ramirez

Karina Ramirez

Auto-generated profile, based on publicly available information

Karina Ramirez

Laboratorio de Microbiología Molecular y Bioactivos, Tecnológico Nacional de México-Instituto Tecnológico de Culiacán , 80220 Culiacán , Mexico

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
KRK Ramirez
K Ramirez
YDY Ditamo
Y Ditamo
LRL Rodriguez
L Rodriguez
WPW L Picking
W L Picking
MRM L van Roosmalen
M L van Roosmalen
MPM F Pasetti
M F Pasetti
Safe and effective immunization of newborns and infants can significantly reduce childhood mortality, yet conventional vaccines have been largely unsuccessful in stimulating the neonatal immune system. We explored the capacity of a novel mucosal antigen delivery system consisting of non-living, non-genetically modified Lactococcus lactis particles, designated as Gram-positive enhancer matrix (GEM), to induce immune responses in the neonatal setting. Yersinia pestis LcrV, used as model protective antigen, was displayed on the GEM particles. Newborn mice immunized intranasally with GEM-LcrV developed LcrV-specific antibodies, Th1-type cell-mediated immunity, and were protected against lethal Y. pestis (plague) infection. The GEM particles activated and enhanced the maturation of neonatal dendritic cells (DCs) both in vivo and in vitro. These DCs showed increased capacities for secretion of proinflammatory and Th1-cell polarizing cytokines, antigen presentation and stimulation of CD4+ and CD8+ T cells. These data show that mucosal immunization with L. lactis GEM particles carrying vaccine antigens represents a promising approach to prevent infectious diseases early in life.

15 May 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KRKarina Ramirez
Karina Ramirez
CCCarmina Cazarez-Montoya
Carmina Cazarez-Montoya
HLHector Samuel Lopez-Moreno
Hector Samuel Lopez-Moreno
NCNohelia Castro-del Campo
Nohelia Castro-del Campo
Escherichia coli O157:H7 has become a global public health and a food safety problem. Despite the implementation of control strategies that guarantee the safety in various products, outbreaks persist and new alternatives are necessary to reduce this pathogen along the food chain. Recently, our group isolated and characterised lytic bacteriophages against E. coli O157:H7 with potential to be used as biocontrol agents in food. To this end, phages need certain requirements to allow their manufacture and application. The aim of this study was to determine the physical stability and allergenic potential of free and microencapsulated (ME) bacteriophage cocktails against E. coli O157:H7. In vitro and in vivo studies were performed to determine phage survival under different pH, gastrointestinal conditions, temperature and UV light intensities. Results showed that the stability of ME phages was significantly (P<0.05) higher than free phages after ultraviolet irradiation, pH conditions between 3 to 7, and exposure to temperatures between at -80°C and 70°C. Both formulations were highly sensitive to very low pH in simulated gastric fluid, but stable in bile salts. In vivo studies in mice confirmed these phages passed through the gastrointestinal tract and were excreted in faeces. In silico, full-length alignment analysis showed that all phage proteins were negative for allergenic potential, but different predicting criteria classified seven phage proteins with a very low probability to be an allergen. In conclusion, these data demonstrated that microencapsulation provided a greater stability to phage formulation under stress conditions and assure a more suitable commercial formulation for the biological control of E. coli O157:H7.

1 August 2012 in Clinical Immunology
Verified
Journal Article
Closed access
KRKarina Ramirez
Karina Ramirez
RWRezwanul Wahid
Rezwanul Wahid
CRCharles Richardson
Charles Richardson
RBRobert F. Bargatze
Robert F. Bargatze
SESamer S. El-Kamary
Samer S. El-Kamary
MPMarcela F. Pasetti
Marcela F. Pasetti

1 May 2006 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ACAlejandra V E Capozzo
Alejandra V E Capozzo
KRKarina RamírEz
Karina RamírEz
JPJohn M. Polo
John M. Polo
JUJeffrey Ulmer
Jeffrey Ulmer
EBEileen M. Barry
Eileen M. Barry
MPMarcela F. Pasetti
Marcela F. Pasetti
Infants younger than age 9 mo do not respond reliably to the live attenuated measles vaccine due the immaturity of their immune system and the presence of maternal Abs that interfere with successful immunization. We evaluated the immune responses elicited by Sindbis virus replicon-based DNA vaccines encoding measles virus (MV) hemagglutinin (H, pMSIN-H) or both hemagglutinin and fusion (F, pMSINH-FdU) glycoproteins in neonatal mice born to naive and measles-immune mothers. Despite the presence of high levels of maternal Abs, neonatal immunization with pMSIN-H induced long-lasting, high-avidity MV plaque reduction neutralization (PRN) Abs, mainly IgG2a, that also inhibited syncytium formation in CD150+ B95-8 cells. IgG secreting plasma cells were detected in spleen and bone marrow. Newborns vaccinated with pMSINH-FdU elicited PRN titers that surpassed the protective level (200 mIU/ml) but were short-lived, had low syncytium inhibition capacity, and lacked avidity maturation. This vaccine failed to induce significant PRN titers in the presence of placentally transferred Abs. Both pMSIN-H and pMSINH-FdU elicited strong Th1 type cell-mediated immunity, measured by T cell proliferation and IFN-γ production, that was unaffected by maternal Abs. Newborns responded to measles DNA vaccines with similar or even higher PRN titers and cell-mediated immunity than adult mice. This study is the first demonstration that a Sindbis virus-based measles DNA vaccine can elicit robust MV immunity in neonates bypassing maternal Abs. Such a vaccine could be followed by the current live attenuated MV vaccine in a heterologous prime-boost to protect against measles early in life.

5 February 2018 in Journal of Food Science and Technology
Verified
Journal Article
Closed access
PDF file
JRJesús J. Rochín-Medina
Jesús J. Rochín-Medina
KRKarina Ramírez
Karina Ramírez
Jesus Gabriel Rangel-PerazaJesus Gabriel Rangel-Peraza
Jesus Gabriel Rangel-Peraza
Yaneth Alejandra Bustos-TerronesYaneth Alejandra Bustos-Terrones
Yaneth Alejandra Bustos-Terrones

1 March 2011 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
JSJakub K. Simon
Jakub K. Simon
KRKarina Ramirez
Karina Ramirez
LCLilian Cuberos
Lilian Cuberos
JCJames D. Campbell
James D. Campbell
JVJean F. Viret
Jean F. Viret
MPMarcela F. Pasetti
Marcela F. Pasetti
Measles remains an important cause of morbidity and mortality among children in the developing world. The goal of this study was to examine measles virus-specific mucosal immune responses in healthy immune ( n = 24; plaque reduction neutralization [PRN] titers of ≥200 mIU/ml) and nonimmune ( n = 24) young adult volunteers who received the monovalent Moraten measles vaccine via intranasal (spray delivery) or subcutaneous immunization. Serum, oral fluid, and nasal wash samples were examined for measles virus-specific and total IgG and IgA on day 0 (prior to vaccination) and on days 14, 28, and 90 after vaccination. Nonimmune subjects vaccinated subcutaneously developed high levels of measles virus PRN, IgG, and IgA antibodies in serum, oral fluid, and nasal washes. Total IgG and secretory IgA (sIgA) titers were increased in nasal washes, and total IgG was increased in oral fluid specimens. There was a strong correlation between PRN and measles virus-specific IgG titers measured in serum, oral fluid, and nasal washes, whereas a weak correlation was found between PRN and measles virus-specific IgA titers. Notably, intranasal measles vaccination resulted in increased production of measles virus-specific sIgA in oral fluid and nasal washes in nonimmune individuals, without evidence of a systemic immune response. In contrast, no significant vaccine-induced responses were observed in immune subjects, regardless of the route of immunization. These results demonstrate that (i) intranasal measles immunization can elicit a mucosal response independent of the induction of serum antibodies and (ii) both mucosal and systemic antibody responses following nasal or subcutaneous immunization are blunted by preexisting measles immunity.